vs
Bioceres Crop Solutions Corp.（BIOX）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$77.6M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -9.6%，领先393.6%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -16.8%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
BIOX vs RIGL — 直观对比
营收规模更大
BIOX
是对方的1.1倍
$69.8M
营收增速更快
RIGL
高出38.0%
-16.8%
净利率更高
RIGL
高出393.6%
-9.6%
两年增速更快
RIGL
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $69.8M |
| 净利润 | $-7.4M | $268.1M |
| 毛利率 | 46.8% | 91.5% |
| 营业利润率 | 9.3% | 33.2% |
| 净利率 | -9.6% | 384.0% |
| 营收同比 | -16.8% | 21.2% |
| 净利润同比 | -20.2% | 1769.2% |
| 每股收益（稀释后） | $-0.12 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRIGL
| Q4 25 | — | $69.8M | ||
| Q3 25 | $77.6M | $69.5M | ||
| Q2 25 | — | $101.7M | ||
| Q1 25 | $60.6M | $53.3M | ||
| Q4 24 | $98.8M | $57.6M | ||
| Q3 24 | $93.3M | $55.3M | ||
| Q2 24 | — | $36.8M | ||
| Q1 24 | $84.0M | $29.5M |
净利润BIOXRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $-7.4M | $27.9M | ||
| Q2 25 | — | $59.6M | ||
| Q1 25 | $-1.6M | $11.4M | ||
| Q4 24 | $605.2K | $14.3M | ||
| Q3 24 | $-6.2M | $12.4M | ||
| Q2 24 | — | $-1.0M | ||
| Q1 24 | $9.8M | $-8.2M |
毛利率BIOXRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | 46.8% | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | 39.4% | 91.7% | ||
| Q4 24 | 42.0% | 89.9% | ||
| Q3 24 | 40.2% | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | 50.8% | 93.1% |
营业利润率BIOXRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | 9.3% | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | 1.5% | 23.9% | ||
| Q4 24 | 14.5% | 28.9% | ||
| Q3 24 | 2.5% | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | 15.7% | -23.6% |
净利率BIOXRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | -9.6% | 40.2% | ||
| Q2 25 | — | 58.6% | ||
| Q1 25 | -2.6% | 21.5% | ||
| Q4 24 | 0.6% | 24.9% | ||
| Q3 24 | -6.6% | 22.5% | ||
| Q2 24 | — | -2.8% | ||
| Q1 24 | 11.6% | -27.9% |
每股收益（稀释后）BIOXRIGL
| Q4 25 | — | $14.11 | ||
| Q3 25 | $-0.12 | $1.46 | ||
| Q2 25 | — | $3.28 | ||
| Q1 25 | $-0.02 | $0.63 | ||
| Q4 24 | $0.00 | $0.82 | ||
| Q3 24 | $-0.10 | $0.70 | ||
| Q2 24 | — | $-0.06 | ||
| Q1 24 | $0.14 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $288.3M | $391.5M |
| 总资产 | $734.9M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资BIOXRIGL
| Q4 25 | — | $155.0M | ||
| Q3 25 | $15.5M | $137.1M | ||
| Q2 25 | — | $108.4M | ||
| Q1 25 | $38.5M | $77.1M | ||
| Q4 24 | $29.2M | $77.3M | ||
| Q3 24 | $32.3M | $61.1M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | $16.4M | $49.5M |
总债务BIOXRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益BIOXRIGL
| Q4 25 | — | $391.5M | ||
| Q3 25 | $288.3M | $117.6M | ||
| Q2 25 | — | $81.9M | ||
| Q1 25 | $345.0M | $18.6M | ||
| Q4 24 | $346.3M | $3.3M | ||
| Q3 24 | $346.0M | $-14.6M | ||
| Q2 24 | — | $-29.9M | ||
| Q1 24 | $348.5M | $-31.7M |
总资产BIOXRIGL
| Q4 25 | — | $513.6M | ||
| Q3 25 | $734.9M | $242.5M | ||
| Q2 25 | — | $206.7M | ||
| Q1 25 | $798.2M | $176.0M | ||
| Q4 24 | $835.2M | $164.0M | ||
| Q3 24 | $827.3M | $139.4M | ||
| Q2 24 | — | $128.4M | ||
| Q1 24 | $836.1M | $126.5M |
负债/权益比BIOXRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BIOXRIGL
| Q4 25 | — | $22.0M | ||
| Q3 25 | $14.4M | $24.0M | ||
| Q2 25 | — | $30.5M | ||
| Q1 25 | $23.3M | $-893.0K | ||
| Q4 24 | $-5.4M | $14.5M | ||
| Q3 24 | $5.2M | $21.7M | ||
| Q2 24 | — | $302.0K | ||
| Q1 24 | $-17.4M | $-5.0M |
现金转化率BIOXRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | -8.85× | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
